First-line camrelizumab plus pemetrexed and carboplatin for advanced non-squamous non-small-cell lung cancer with brain metastases (CAP-BRAIN): final results of a multicentre, open-label, single-arm, phase 2 trial in China.

EClinicalMedicine · 2025 · PMC12661349 · PMID 41324015

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a positive trendno p-value reported

Additionally, a positive trend toward improvement in cognitive function and QOL of patients was noted.

also in 11,005 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.